MarketCap
Facebook
X
Telegram
Longeveron Cash Conversion Cycle | LGVN
Annual Cash Conversion Cycle Longeveron
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -212 | -250 | -809 | -400 | 7.69 | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.69 | -809 | -333 |
Quarterly Cash Conversion Cycle Longeveron
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -6.74 K | -278 | -491 | - | -710 | -722 | -456 | - | -1.14 K | 40.4 | 51.4 | - | -225 | -132 | -268 | - | -342 | -170 | -499 | - | -97.2 | -190 | -81 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 51.4 | -6.74 K | -692 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
284 | $ 291.22 | 1.06 % | $ 515 B |  USA |
 |
22nd Century Group
XXII
|
108 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
64.5 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
337 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
Theratechnologies
THTX
|
178 | - | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
-8.32 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Gilead Sciences
GILD
|
115 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
31.7 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
Insmed Incorporated
INSM
|
173 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
88.2 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
19.2 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-4.27 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mesoblast Limited
MESO
|
0.01 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Adaptimmune Therapeutics plc
ADAP
|
-24.8 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-284 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-15.2 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
349 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
Merck & Co.
MRK
|
110 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
459 | - | - | $ 2.02 B | USA |
 |
Curis
CRIS
|
64.7 | $ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
137 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
-32.7 | - | - | - |  Russia |
 |
CorMedix
CRMD
|
359 | $ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
0.04 | $ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
Pfizer
PFE
|
189 | $ 29.39 | -0.22 % | $ 167 B | USA |
 |
Orgenesis
ORGS
|
25.8 | - | -33.86 % | $ 61.2 M | USA |
 |
Фармсинтез
LIFE
|
-15.9 | - | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
6.97 | $ 7.93 | 0.51 % | $ 427 M | USA |